Study Characterizes Pneumonitis Risk With Immunotherapeutic Agents
- This topic has 1 reply, 2 voices, and was last updated 7 years, 9 months ago by
.
Viewing 2 posts - 1 through 2 (of 2 total)
-
Posts
-
Pneumonitis occurs in approximately 5% of cancer patients treated with anti–programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy agents, according to a new analysis. The complication tends to be low grade and easily resolved, though it can worsen and result in death in rare cases.
Viewing 2 posts - 1 through 2 (of 2 total)
- The forum ‘New Developments’ is closed to new topics and replies.